TY - JOUR AU - Heeley E. AU - Stapf C. AU - Robinson T. AU - Hata J. AU - Zhang S. AU - Lindley R. AU - Chen X. AU - Davies L. AU - Arima H. AU - Delcourt C. AU - Sato S. AU - Anderson Craig AU - Zheng D. AU - Hackett M AU - Lavados P. AU - Salman R. AU - Sandset E. AU - Chalmers J. AB -

OBJECTIVE: To clarify associations between intracerebral hemorrhage (ICH) location and clinical outcomes among participants of the main phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). METHODS: Associations between ICH sites and poor outcomes (death [6] or major disability [3-5] of modified Rankin Scale) and European Quality of Life Scale (EQ-5D) utility scores at 90 days were assessed in logistic regression models. RESULTS: Of 2,066 patients included in the analyses, associations were identified between ICH sites and poor outcomes: involvement of posterior limb of internal capsule increased risks of death or major disability (odds ratio [OR] 2.10) and disability (OR 1.81); thalamic involvement increased risks of death or major disability (OR 2.24) and death (OR 1.97). Involvement of the posterior limb of the internal capsule, thalamus, and infratentorial sites were each associated with poor EQ-5D utility score (

AD - From The George Institute for Global Health and The University of Sydney (C.D., S.S., E.C.S., D.Z., X.C., M.L.H., E.H., R.I.L., J.C., C.S.A.); Royal Prince Alfred Hospital (C.D., L.D., J.C., C.S.A.), Camperdown, Australia; National Cerebral and Cardiovascular Center (S.S.), Osaka, Japan; Department of Neurology (S.Z.), West China Hospital, Sichuan University, Chengdu; Oslo University Hospital (C.S.), Norway; The University of Central Lancashire (M.L.H.), UK; Department of Preventive Medicine and Public Health (H.A.), Faculty of Medicine, Fukuoka University; Center for Cohort Studies (J.H.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Division of Clinical Neurosciences (R.A.-S.S.), Centre for Clinical Brain Sciences, University of Edinburgh; Department of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Diseases (T.R.), University of Leicester, UK; Clinica Alemana de Santiago (P.M.L.), Facultad de Medicina Clinica Alemana Universidad del Desarrollo; Facultad de Medicina (P.M.L.), Universidad de Chile, Santiago; Westmead Hospital Clinical School (R.I.L.), Westmead, Australia; Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM) (C.S.), Departement de Neurosciences, Universite de Montreal, Canada; and The George Institute China (C.S.A.), Peking University Health Sciences Center, Beijing, China.
From The George Institute for Global Health and The University of Sydney (C.D., S.S., E.C.S., D.Z., X.C., M.L.H., E.H., R.I.L., J.C., C.S.A.); Royal Prince Alfred Hospital (C.D., L.D., J.C., C.S.A.), Camperdown, Australia; National Cerebral and Cardiovascular Center (S.S.), Osaka, Japan; Department of Neurology (S.Z.), West China Hospital, Sichuan University, Chengdu; Oslo University Hospital (C.S.), Norway; The University of Central Lancashire (M.L.H.), UK; Department of Preventive Medicine and Public Health (H.A.), Faculty of Medicine, Fukuoka University; Center for Cohort Studies (J.H.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Division of Clinical Neurosciences (R.A.-S.S.), Centre for Clinical Brain Sciences, University of Edinburgh; Department of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Diseases (T.R.), University of Leicester, UK; Clinica Alemana de Santiago (P.M.L.), Facultad de Medicina Clinica Alemana Universidad del Desarrollo; Facultad de Medicina (P.M.L.), Universidad de Chile, Santiago; Westmead Hospital Clinical School (R.I.L.), Westmead, Australia; Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM) (C.S.), Departement de Neurosciences, Universite de Montreal, Canada; and The George Institute China (C.S.A.), Peking University Health Sciences Center, Beijing, China. canderson@georgeinstitute.org.au. AN - 28235817 BT - NeurologyNeurologyNeurology C2 - PMC5386433 DP - NLM ET - 2017/02/27 J2 - Neurology LA - eng LB - AUS
CHINA
NMH
FY17 M1 - 15 N1 - Delcourt, Candice
Sato, Shoichiro
Zhang, Shihong
Sandset, Else Charlotte
Zheng, Danni
Chen, Xiaoying
Hackett, Maree L
Arima, Hisatomi
Hata, Jun
Heeley, Emma
Salman, Rustam Al-Shahi
Robinson, Thompson
Davies, Leo
Lavados, Pablo M
Lindley, Richard I
Stapf, Christian
Chalmers, John
Anderson, Craig S
INTERACT2 Investigators
United States
Neurology. 2017 Apr 11;88(15):1408-1414. doi: 10.1212/WNL.0000000000003771. Epub 2017 Feb 24. N2 -

OBJECTIVE: To clarify associations between intracerebral hemorrhage (ICH) location and clinical outcomes among participants of the main phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). METHODS: Associations between ICH sites and poor outcomes (death [6] or major disability [3-5] of modified Rankin Scale) and European Quality of Life Scale (EQ-5D) utility scores at 90 days were assessed in logistic regression models. RESULTS: Of 2,066 patients included in the analyses, associations were identified between ICH sites and poor outcomes: involvement of posterior limb of internal capsule increased risks of death or major disability (odds ratio [OR] 2.10) and disability (OR 1.81); thalamic involvement increased risks of death or major disability (OR 2.24) and death (OR 1.97). Involvement of the posterior limb of the internal capsule, thalamus, and infratentorial sites were each associated with poor EQ-5D utility score (

PY - 2017 SN - 1526-632X (Electronic)
0028-3878 (Linking) SP - 1408 EP - 1414 ST - NeurologyNeurology T2 - NeurologyNeurologyNeurology TI - Intracerebral hemorrhage location and outcome among INTERACT2 participants VL - 88 Y2 - FY17 ER -